First patient dosed with Transgene’s TG6002 in colorectal cancer with liver metastases

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the first patient has successfully received TG6002, via an intrahepatic artery (IHA) infusion, as a locoregional treatment for unresectable liver metastases from colorectal cancer (CRLM).